219 related articles for article (PubMed ID: 30093656)
21. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
22. IL-1β is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer.
Zhao S; Xing S; Wang L; Ouyang M; Liu S; Sun L; Yu H
Sci Rep; 2023 Aug; 13(1):12763. PubMed ID: 37550397
[TBL] [Abstract][Full Text] [Related]
23. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
24. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
[TBL] [Abstract][Full Text] [Related]
25. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.
Zeng Y; Cao Y; Liu L; Zhao J; Zhang T; Xiao L; Jia M; Tian Q; Yu H; Chen S; Cai Y
Cell Death Dis; 2019 Sep; 10(10):720. PubMed ID: 31558699
[TBL] [Abstract][Full Text] [Related]
26. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
27. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.
Zhang S; Mercado-Uribe I; Xing Z; Sun B; Kuang J; Liu J
Oncogene; 2014 Jan; 33(1):116-28. PubMed ID: 23524583
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
29. Single-Cell MTT: A Simple and Sensitive Assay for Determining the Viability and Metabolic Activity of Polyploid Giant Cancer Cells (PGCCs).
Mirzayans R; Andrais B; Murray D
Methods Mol Biol; 2024; 2825():293-308. PubMed ID: 38913317
[TBL] [Abstract][Full Text] [Related]
30. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Amith SR; Wilkinson JM; Baksh S; Fliegel L
Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
[TBL] [Abstract][Full Text] [Related]
31. Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
Eitaki M; Yamamori T; Meike S; Yasui H; Inanami O
BMC Cancer; 2012 Oct; 12():469. PubMed ID: 23057787
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells.
Wilson AL; Schrecengost RS; Guerrero MS; Thomas KS; Bouton AH
PLoS One; 2013; 8(6):e65678. PubMed ID: 23762409
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.
Humphries BA; Buschhaus JM; Chen YC; Haley HR; Qyli T; Chiang B; Shen N; Rajendran S; Cutter A; Cheng YH; Chen YT; Cong J; Spinosa PC; Yoon E; Luker KE; Luker GD
Mol Cancer Res; 2019 May; 17(5):1142-1154. PubMed ID: 30718260
[TBL] [Abstract][Full Text] [Related]
34. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
35. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
36. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
Gari HH; DeGala GD; Ray R; Lucia MS; Lambert JR
Cancer Lett; 2016 Oct; 380(2):505-512. PubMed ID: 27452906
[TBL] [Abstract][Full Text] [Related]
37. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
38. Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells.
Leve F; Marcondes TG; Bastos LG; Rabello SV; Tanaka MN; Morgado-Díaz JA
Eur J Pharmacol; 2011 Dec; 671(1-3):7-17. PubMed ID: 21968138
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
40. Syncytin 1, CD9, and CD47 regulating cell fusion to form PGCCs associated with cAMP/PKA and JNK signaling pathway.
Fei F; Li C; Wang X; Du J; Liu K; Li B; Yao P; Li Y; Zhang S
Cancer Med; 2019 Jun; 8(6):3047-3058. PubMed ID: 31025548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
